FDA Panel Backs Novel Cancer Blood Test from Grail

Buffalo, NY, September 23, 2026 —

An advisory panel convened by the U.S. Food and Drug Administration (FDA) has provided a positive endorsement for a new blood test designed to detect cancer, developed by the company Grail. The development was reported by niagara-gazette.com, a local news outlet based in Buffalo.

The test, described as novel, aims to identify various types of cancer through a single blood draw. Details regarding the specific types of cancer the test is intended to detect, its reported accuracy rates, or the timeline for its potential regulatory approval by the FDA were not explicitly provided in the initial report.

Grail, the company behind the blood test, is focusing on early cancer detection through its technology. The endorsement from an FDA panel represents a significant step in the review process for such medical diagnostics. However, the panel’s recommendations are advisory, and the final decision on whether to approve the test rests with the FDA itself. Information concerning the criteria used by the panel in its endorsement, such as clinical trial data or efficacy studies, was not detailed.

The report originating from niagara-gazette.com highlights local interest in significant healthcare and technology advancements. The specific proceedings of the FDA panel, including the names of participating experts or the duration of their deliberations, were not made public in the summary of the trend.

Further details concerning the potential implications of this test for public health, its accessibility, or the specific patient populations it might serve are also not available at this time. The company Grail, and the test’s regulatory pathway, remain subjects of ongoing interest as more information becomes available.

Story summarized from the original created by MATTHEW PERRONE and LAURAN NEERGAARD | Associated Press on www.niagara-gazette.com, see more information here.

Media gallery